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The immunogenicity of protein therapeutics is an important safety and efficacy concern
during drug development and regulation. Strategies to identify individuals and subpopula-
tions at risk for an undesirable immune response represent an important unmet need. The
major histocompatibility complex (MHC)–associated peptide proteomics (MAPPs) assay
directly identifies the presence of peptides derived from a specific protein therapeutic on
a donor’s MHC class II (MHC-II) proteins. We applied this technique to address several
questions related to the use of factor VIII (FVIII) replacement therapy in the treatment
of hemophilia A (HA). Although .12 FVIII therapeutics are marketed, most fall into
3 categories: (i) human plasma-derived FVIII (pdFVIII), (ii) full-length (FL)–recombinant
FVIII (rFVIII; FL-rFVIII), and (iii) B-domain–deleted rFVIII. Here, we investigated whether
there are differences between the FVIII peptides found on the MHC-II proteins of the same
individual when incubated with these 3 classes. Based on several observational studies
and a prospective, randomized, clinical trial showing that the originally approved rFVIII
products may be more immunogenic than the pdFVIII products containing von Willebrand
factor (VWF) in molar excess, it has been hypothesized that the pdFVIII molecules yield/
present fewer peptides (ie, potential T-cell epitopes). We have experimentally tested this
hypothesis and found that dendritic cells from HA patients and healthy donors present
fewer FVIII peptides when administered pdFVIII vs FL-rFVIII, despite both containing
the same molar VWF excess. Our results support the hypothesis that synthesis of pdFVIII
under physiological conditions could result in reduced heterogeneity and/or subtle
differences in structure/conformation which, in turn, may result in reduced FVIII
proteolytic processing relative to FL-rFVIII.
Introduction
The most severe complication of factor VIII (FVIII) replacement therapy, used to treat hemophilia A (HA),
is the development of FVIII-neutralizing antibodies or “inhibitors.”1 More broadly, immunogenicity is a
safety-and-efficacy concern during the development and licensure of therapeutic proteins.2 Numerous
FVIII products, either purified from human plasma (plasma-derived FVIII [pdFVIII]) or generated using
recombinant DNA technology (recombinant FVIII [rFVIII]), are in clinical use.3,4 Recent epidemiological
studies5-8 and a prospective randomized clinical control trial9 suggest that the rFVIII products may be
Submitted 22 December 2018; accepted 18 March 2019. DOI 10.1182/
bloodadvances.2018030452.
The full-text version of this article contains a data supplement.
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more immunogenic than the pdFVIII products. Although hypoth-
eses have been advanced to explain this difference,10 testing
these experimentally has been challenging. The few experimental
studies that have been conducted suggest that von Willebrand
factor (VWF) inhibits FVIII endocytosis into monocyte-derived
dendritic cells (MoDCs) and, therefore, limits their presentation of
FVIII-derived peptides.11-13
The major histocompatibility complex (MHC)–associated peptide
proteomics (MAPPs) assay is a powerful tool that identifies the
therapeutic protein-derived peptides presented on the MHC class II
(MHC-II) molecules expressed by a subject’s antigen-presenting
cells.14-16 Studies have shown that peptide–MHC-II affinity is
a good predictor of immunogenicity.17-19 However, evaluation
of peptide–MHC-II affinity alone incorrectly presupposes that
all potential peptides will be generated. Protein processing and
presentation are both necessary to elicit antigen-specific T-cell
responses.20,21 Using peptide pools to identify T-cell epi-
topes does not address the question of whether the peptide(s)
identified as candidate epitopes can be generated by the MoDC
proteolytic machinery. Conversely, T-cell proliferation mediated
by the intact protein does not allow identification of specific T-cell
epitope(s).
The mass spectrometry (MS)–based MAPPs assay is an analytical
tool that provides information about both protein processing and
peptide presentation.22 In studying immunogenicity, we used
this approach to characterize a neosequence in an engineered
variant of FVIIa that was more immunogenic than the wild-type
molecule.23 The study used a range of in silico assessments and
in vitro and ex vivo assays for the immunological characterization of
the neosequences; the MAPPs assay was the only analytical
tool that could demonstrate that the foreign antigen was both
processed and presented by the immune system. Several studies
have also used the MAPPs assay to identify the FVIII-derived
peptides presented by MHC-II proteins.24-26
The MAPPs technology offers an experimental platform for
testing hypotheses related to product-specific immunogenicity of
different FVIII concentrates. For instance, the protection of T-cell
epitopes by VWF10,27 and differences in the cellular processing
of pdFVIII and rFVIII have been proposed to explain differences
in clinical immunogenicity.11,12 These hypotheses can be tested
using MAPPs assays, which permit the comparison of peptide–MHC-II
repertoires when cells are treated with the various therapeutic FVIII
products.
Here, using MAPPs, we provide experimental evidence that: (i) the
number of unique FVIII-derived peptides isolated, average length of
peptides, and range of peptide lengths were comparable for MHC-II
proteins immunoprecipitated from MoDCs from HA patients or
healthy blood donors; (ii) for each subject, FVIII-derived peptides
identified by the MAPPs assay were enriched for peptides with high
affinities for the MHC-II variants from which they were eluted
compared with a million peptides of comparable lengths randomly
obtained from the human proteome; (iii) when MoDCs from the
same donor were exposed to full-length (FL)-rFVIII or B-domain–
deleted (BDD)-rFVIII, similar peptides were identified on their
MHC-II molecules (as expected, cells incubated with BDD-rFVIII did
not present peptides originating from the B domain); and (iv) when
MoDCs from the same donor were incubated with FL-rFVIII or
pdFVIII (both in the presence of pdVWF), fewer FVIII peptides were
recovered from the pdFVIII compared with FL-rFVIII. These results
indicate that the cellular sources (ie, healthy human pooled plasma-
derived vs Chinese hamster ovary–expressed) of the FVIII and/or
manufacturing processes may differentially affect their processing




Cells. Peripheral blood mononuclear cells were isolated
from 6 HA patients by leukopheresis at the University of North
Carolina Apheresis Unit. The procedure was performed follow-
ing informed consent under institutional review board study
number 14-0582. The cells were cryopreserved in 10% dimethyl
sulfoxide. Each 1.8-mL cryotube contained ;20 3 106 cells.
Peripheral blood mononuclear cells were also obtained from an
additional 15 unrelated healthy blood donors at the Adden-
brooke’s Hospital (Cambridge, United Kingdom) after informed
consent.
FVIII and VWF sample preparation. Beriate, a marketed
pdFVIII product provided by CSL Behring GmbH, contains pdVWF
(supplemental Figure 1). For this study, pdVWF was removed from
reconstituted Beriate using a VIIISelect affinity resin (GE Health-
care) using an VIIISelect affinity column. FVIII activity in the final
samples was determined by chromogenic FVIII activity assay
(Chromogenix Coamatic Factor VIII; Diapharma). pdVWF (sup-
plemental Figure 2) was provided as an intermediate precipitate
of the plasma-fractioning process by CSL Behring GmbH. pdFVIII
bound to pdVWF was separated from the precipitate through
a size-exclusion chromatography step using HiPrep Sephacryl
S500 (GE Healthcare) (supplemental Figure 3) using a N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid (HEPES) buffer
containing 400 nM calcium chloride, as described previously.28
Fractions 1.A.2 to 2.A.2. from the size-exclusion chromatography
were used. Residual FVIII in final preparations was negligible
(0.004% mass). Using human MoDC-based assays, the uptake of
tFVIIIs in the presence of pdVWF was evaluated in a concentration-
dependent manner, as described previously.12 We identified a
minimum molar ratio of FVIII to VWF, which is required to effectively
inhibit FVIII endocytosis by MoDCs in vitro (data not shown).29 Both
pdFVIII and rFVIII products (145 nM final concentration) were
individually combined with pdVWF at a molar ratio of 1:13.4 prior to
use in the MAPPs assays.
Methods
In vitro profiling of peptides displayed by HLAcII-DR, -DP,
and -DQ after uptake by MoDCs. The study was performed by
ProImmune using the ProPresent Antigen Presentation Assay (see
Rombach-Riegraf et al,30 Xue et al,31 Ventura et al,32 and Gouw
et al33 for details). Monocytes were isolated from the mononuclear
cell fraction of peripheral blood samples by positive selection and
differentiated in vitro into immature MoDCs. The immature MoDCs
were: (i) cultured in the presence of 1 of the 3 FVIIIs (pdFVIII,
FL-rFVIII, BDD-rFVIII), each containing 13.4 molar excess pdVWF,
and (ii) matured in the presence of the same preincubated FVIII-
plus-pdVWF mix. The mature MoDCs were harvested and lysed.
HLA class II (HLAcII)-DR, -DQ, and -DP molecules were recov-
ered from the cell lysate using immune-affinity columns. The
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HLAcII-bound peptides were then eluted and processed for further
analysis by high-resolution-sequencing MS (liquid chromatography–
tandem MS). The resulting data were compiled and analyzed using
sequence analysis software referencing the Swiss-Prot Human
Proteome Database with the incorporated test item sequence(s).
Liquid chromatography–tandem MS–based identification of peptide
sequences was based on scoring algorithms and statistical signifi-
cance determination. The likelihood of peptides to be real identities
is described by their expect value (EV) and by the false discovery
rate (FDR) obtained by searching an unrelated database. The EV
considers specific features of the experimental MS/MS spectrum,
for example, the number of peaks that match predicted fragments
from a peptide sequence in the database. The EV provides a
statistical significance for the peptide identification and it is defined as
being reflective of the number of assignments with equal (or better)
scores that are expected to occur by chance alone. The lower this
value, the higher the probability the assignment is correct. EV# 0.05.
was used to report significant hits as recommended by current
guidelines for documentation of peptide and protein identification
by MS.34 An FDR is determined by repeating the search using
identical searching parameters against a “decoy” database, where
the sequences have been reversed or randomized. The number of
matches that are found with the decoy database is an estimate of
the number of false positives that are present in the results from
the real or “target” database. The FDR can be expressed as the
total false positives divided by the sum of true positives and false
positives. Identifications reported with EV # 0.05 typically have
FDRs ,1%.
Reads with sequences that matched both the FL protein sequence
and a variant were counted once if the polymorphism was not
included in the matched region. Peptides derived from BDD-rFVIII
are numbered based on their position in the FL-FVIII. When cells
from the same subject were treated with 2 products, peptides were
identified as unique to 1 product if no peptides at that location
were identified for the other product. In some cases, peptides with
identical cores but different lengths were identified following
treatment with different products; fragments ,9 amino acids (aa)
in length were disregarded.
HLA typing. For HLA typing, we used next-generation se-
quencing for typing the DRB1, DPB1, and DQB1 loci. Next-
generation sequencing typing allows precise resolution of HLA
types to precise 4-digit allelic level.
Computational model of FVIII structure. PyMOL
(Schrödinger) was used for mapping of the MAPPs assay–
derived peptides onto the FVIII crystal structure. Structure of FVIII
was obtained from https://www.rcsb.org/ using Protein Data Bank
identifier (PDB ID) 2R7E. The information about the interaction
between FVIII and VWF was obtained from published sources.35-39
Data analysis
The probability density plot is the comparison of 4 indepen-
dent sets of peptides: (i) a random set of 1 000 000 15-mer
sequences computationally generated; (ii) all human proteins in
the Swiss-Prot database were computationally cleaved into
15-mer peptides, and 1 000 000 random peptides from this list
resulted in a data set of 912 997 nonredundant peptides; (iii) all
overlapping 15-mer peptides derived from the FVIII and VWF
sequences (5117 peptides); and (iv) the set of peptides from the
MAPPs assay consists of all peptides identified in the assay with an
EV score,0.05. For each subject, the minimum percent-rank score
of each peptide for that subject’s HLA alleles was recorded, and the
4 sets of scores were plotted as histograms and smoothed using
Gaussian kernel density estimation. For each peptide, the predicted
affinity to each HLA variant identified in that subject was computed
using netMHCIIpan version 3.2.40
Data analyses were performed using Python (https://www.python.org)
and R (https://www.R-project.org/). Graphics were generated using
ggplot241 matplotlib.42
Results
FVIII peptides presented by MHC-II molecules on
MoDCs from HA patients and healthy blood donors
FVIII peptides were identified on MHC-II proteins isolated from
MoDCs incubated with FL-rFVIII plus VWF in a MAPPs assay. The
cells were obtained from 6 HA patients (supplemental Table 1
describes patient characteristics) and 15 unrelated healthy blood
donors. Figure 1A summarizes the distribution of HLAcII-DRB1
alleles in the 2 groups and frequencies of these alleles in different
populations. The DR, DP, and DQ isomers of the MHC-II proteins
were captured separately using specific immunoaffinity columns.
Peptides associated with the MHC-II proteins were identified
by mass-spectrometric analyses. Peptides from endogenous
proteins and the FVIII products coincubated with the MoDCs
are presented by the MHC-II. The computational identification
of FVIII-derived peptides with a FDR of ,1% are described in
“Methods.” The number of unique FVIII peptides isolated, total
number of peptides identified, the average length of peptides, and
range of peptide lengths in the 2 groups are shown in Table 1.
There are no significant differences in these parameters between
the HA patients and healthy donors. Similarly, when MoDCs
obtained from HA patients or healthy donors were incubated with
FVIII (either FL-rFVIII plus pdVWF or pdFVIII plus pdVWF), all
unique FVIII peptides identified on MHC-II proteins showed
comparable locations on the FVIII primary sequence (Figure 1B-C).
Unique peptides are defined as nonoverlapping regions of the
proteins found in only 1 of the 2 proteins compared. We also
compared the number of peptides identified on DR, DP, and DQ
isomers and determined that almost 80% of the peptides
identified were presented by the DR molecules (Figure 1D).
Peptide–MHC-II affinity is a necessary but not
sufficient condition for peptide presentation on
MHC-II molecules
Peptide–MHC-II–binding affinity is often used as a surrogate
marker for immunogenicity.17,43,44 We tested the hypothesis that
peptides with higher affinity to MHC-II proteins are more likely
to be presented by the MoDCs. We generated 3 virtual data
sets of peptides (see “Methods” for details): (i) overlapping
15-mer peptides derived from FVIII and VWF, (ii) million randomly
generated peptides, and (iii) million peptides from the human
proteome. We estimated the peptide–MHC-II affinities (expressed
as a percentile score) for each of these data sets using the MHC-II
variants identified in each subject (Figure 2A). The percentile
score expresses the rank of a particular peptide–MHC-II affinity in
an ordered list of all peptide–MHC-II affinities for that particular
MHC-II variant. In large data sets, peptides of all percentile scores
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(affinities) are equally likely to be found. Thus, as expected, the
probability distributions of peptides in all 3 virtual data sets are a flat
line. In sharp contrast, the FVIII peptides identified on the MHC-II
proteins isolated from MoDCs are skewed to the left, which
indicates a greater probability of finding peptides with higher affinity.
This observation was true for FVIII peptides identified on MHC-II
proteins isolated from all 21 subjects (Figure 2A; supplemental
Figure 4). Although all FVIII peptides identified on MoDCs
bind with high affinity to 1 or more of their expressed MHC-II
molecules, only a subset of peptides that binds with high affinity
to an individual subject’s MHC-II variants is identified in the
MAPPs assay (Figure 2B). In characterizing the MAPPs assay,
we used the FL-rFVIII plus pdVWF. In subsequent studies, we
compared the effect of different product classes and protein-
protein interactions on peptide processing and presentation by
MoDCs.
FL-rFVIII and BDD-rFVIII; comparison of peptide
presentation on MHC-II molecules
MoDCs from the same individual were incubated with either FL-rFVIII
plus pdVWF or BDD-rFVIII plus pdVWF in the MAPPs assay. Fewer
unique peptides were identified from the MHC-II proteins when
cells were incubated with BDD-rFVIII plus pdVWF (Figure 3).
However, all the peptides that were unique to FL-rFVIII were
localized to the B domain (Figure 3).
Comparing peptide presentation on MHC-II molecules
following incubation with rFVIII and pdFVIII products
Some clinical studies suggest that specific FVIII products may
present a higher immunogenicity risk whereas other studies
show that the risks are statistically equivalent.5-8,45-47 The Study
on Inhibitors in Plasma-Product Exposed Toddlers (SIPPET), a
prospective randomized clinical trial, reported a 1.87-fold increase
in inhibitors in previously untreated patients treated with rFVIII
compared with pdFVIII.9 We compared FL-rFVIII plus pdVWF and
pdFVIII plus pdVWF with respect to presentation of peptides by
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Figure 1. Identification of FVIII peptides on MoDCs obtained from HA patients and healthy blood donors using the MAPPs assay. (A) HLAcII-DRB1 alleles
of subjects used in this study. The blue shading shows whether a particular allele was found in HA patients or healthy donors. Frequencies of each allele in various
demographic groups are listed and identified on a scale from white (0) to red (15%). (B-C) Peptides identified in the MAPPs assay on DRB1-based DR molecules when
MoDCs were incubated with FL-rFVIII plus pdVWF (B) or pdFVIII plus pdVWF (C). The peptides identified in cells from HA patients are shown in red; peptides identified in
healthy donors are shown in blue. (D) Number of FVIII peptides identified on DR, DP, and DQ molecules in the MAPPs assay when APCs were incubated with FL-rFVIII
plus pdVWF.
Table 1. Overview of FVIII peptides identified in cells obtained from
HA patients and normal donors
HA patients Healthy blood donors
No. of subjects 6 15
No. of unique peptides 20 27
No. of peptides 1126 2713
Average peptides per subject 187.67 181.07
Average peptide length, aa 15.9 16.6
Maximum peptide length, aa 40 36
Minimum peptide length, aa 12 10
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VWF, we isolated pdFVIII free of pdVWF and reconstituted both
FL-rFVIII and pdFVIII with excess pdVWF at a molar ratio of 1:13.4
(see “Methods”). This strategy allows us to compare processing
and MHC-II presentation of FL-rFVIII and pdFVIII under identical
conditions that mimic the in vivo scenario where, due to the high
affinity of the FVIII-VWF interaction, rFVIII products once infused
would rapidly associate with VWF. We found that incubation of
MoDCs with pdFVIII plus pdVWF results in presentation of fewer
peptides than when the same MoDCs are incubated with FL-rFVIII
plus pdVWF (Figure 4A). Although there are differences in the
number of peptides presented by each donor, cells from all donors
present more peptides when incubated with FL-rFVIII plus pdVWF
compared with pdFVIII plus pdVWF. The location of the pep-
tides identified following incubation with FL-rFVIII plus pdVWF or
pdFVIII plus pdVWF for a typical subject is shown in Figure 4B
(data for all patients, individually, is provided in supplemental
Figure 5). We also pooled the data to determine the location of all
FVIII peptides protected against MHC-II presentation with pdFVIII,
that is, not identified when pdFVIII was incubated with the MoDCs
(Figure 4C). These results show that across multiple donors there
are differences in the processing and presentation of FL-rFVIII and
pdFVIII by MoDCs. Differences in the processing and presentation
of FL-rFVIII and pdFVIII (even when both are protected by VWF)
could contribute to the differences in the reported clinical
immunogenicity of these products. However, additional studies
are required to understand the molecular mechanisms (see
“Discussion”).
Identification of peptides derived from VWF on
MHC-II molecules
Because in the experiments described previously (and reported in
Figure 4) the 3 different FVIII products were incubated with pdVWF,
we also identified the pdVWF peptides found to be bound to the
MHC-II molecules. Although there are a few exceptions, in general,
more VWF peptides are presented when cells are incubated with
VWF in the presence of FL-rFVIII (compared with pdFVIII) (Figure 5A).
A
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Figure 2. Affinities of FVIII peptides identified on MoDCs. (A) The distribution of percentile-rank scores predicted by netMHCIIpan3.2 for all peptides found in the
MAPPs assay for a single healthy donor, D1098 (black, shaded), compared with the distribution of percentile-rank scores for 1 3 106 random strings of 15 aa (green),
1 3 106 random 15 mers selected from the human proteome (red), and all 15 mers from FVIII and VWF (blue). Peptides found in the MAPPs assay were more likely to have
high binding affinity to the patients’ alleles as shown by the greater probability of finding lower percentile rank scores for these peptide/MHC-II binding pairs. The other
3 distributions were close to flat which can be expected from a random distribution of peptides. (B) Peptides identified in the MAPPs assay following incubation with FL-rFVIII
plus VWF. Location of the peptides is shown on the primary sequence of FVIII and they are color-coded for the subjects who provided the MoDCs. The gray backdrop shows
the predicted number of subjects whose MHC-II variants would bind peptides at each location with high affinity (percentile rank ,5%) based on netMHCIIpan predictions.
Peptides found in the MAPPs assay were found in regions predicted to be binding regions by netMHCIIpan3.2. Not all regions predicted to be binding regions were found
in the assay.
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The location, on the primary sequence of VWF, of all peptides
identified is shown in Figure 5B.
Mapping the peptides identified using the MAPPs
assay on the structure of FVIII
The crystal structure of FVIII (PDB ID 2R7E), generated using PyMOL
is depicted in Figure 6. Several studies have used site-directed
mutagenesis and antibody competition as well as electron microscopy
and mass spectrometry to identify the sites of interaction between
VWF and FVIII.35-39 The known locations of FVIII-VWF interac-
tions are depicted in Figure 6A. In the current study, several
peptides were identified when cells were incubated with FL-rFVIII
plus pdVWF that were not identified following incubation with
pdFVIII plus pdVWF (Figure 6B). VWF-mediated protection of
FVIII processing would suggest that the peptides that are not
presented in the presence of VWF would be located at or near the
sites of VWF-FVIII interactions. However, our results show that
these peptides do not necessarily locate to the sites of VWF-FVIII
interaction.
Identification of potential T-cell epitopes on FVIII
based on the MAPPs assay
We have shown that there is considerable variation between
subjects with respect to the peptides presented on MHC-II
molecules (Figures 3-5). Some of these differences may arise due
to the distinct MHC-II variants on MoDCs from different subjects. The
subjects in this study covered MHC-II variants that occur in;50% of
the world population (Figure 7A). Moreover, the frequencies of these
variants are comparable to those found in this population. The MHC-II
repertoire is 1 of the most diverse in the human genome and MAPPs
assays are technically challenging, labor intensive, and expensive
to carry out. Thus, it may be useful to pool data from different
studies to develop a comprehensive list of FVIII peptides that can
be processed and presented to T-cell receptors. In addition to this
study, 2 previous studies,24,25 using 9 and 4 donors, respectively,
have identified FVIII peptides on MHC-II proteins following
incubation with FL-rFVIII. We pooled the data for FVIII peptides
identified using the MAPPs assays (Figure 7B). Together, the
antigen-presenting cells used in these studies represent 57.9%
of MHC-II variants in the world population. The peptides identi-
fied in the previous studies covered 27.3% of the total length
of FVIII. The peptides identified in our study included 84.4% of
those positions found in the previous studies and novel peptides
covering an additional 19.0% of FVIII.
Discussion
We present MAPPs data from MoDCs derived from HA patients
and healthy blood donors incubated with different FVIII products.
Together, these subjects provide an adequate coverage of MHC-II
variants (Figure 1A). The number and location of peptides identi-
fied on cells obtained from HA patients or healthy blood donors
are similar (Figure 1B-C). This is important as MAPPs assays
require large numbers of cells and obtaining these from
patients with bleeding disorders can be challenging. In addition,
we demonstrate the value of the MAPPs assay as complementary to
peptide–MHC-II binding assessments as a risk factor for immuno-
genicity. The peptides identified on MHC-II proteins are all enriched
for high-affinity binders (Figure 2A), providing a mechanistic justifi-
cation for the positive association between peptide–MHC-II affinity
and immune responses.23,48-50 Moreover, peptide-MHC-II affinity is
increasingly being used as a surrogate marker in nonclinical studies
that seek to estimate the immunogenicity risk during drug develop-
ment.2,17 The use of peptides in assessing whether immunogenicity
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Figure 3. Comparison of FVIII peptides identified in a MAPPs assay following incubation of MoDCs with FL-rFVIII plus pdVWF or BDD-rFVIII plus
pdVWF. (A) Pooled data for all subjects showing location and frequencies of peptides identified in the MAPPs assay following incubation of MoDCs with FL-rFVIII plus
pdVWF (blue) or BDD-rFVIII plus pdVWF (red). (B) Location and frequencies of peptides identified following incubation with FL-rFVIII plus VWF where no peptides were
found after incubation with BDD-rFVIII plus VWF are shown in green. The x-axis represents the primary sequence of FL-FVIII and the different FVIII domains are depicted
on the figure.
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not taken into account (see “Introduction”). Only peptides that
have successfully undergone protein processing and peptide
presentation are identified in the MAPPs assay whereas peptide–
MHC-II binding measurements/estimates cannot account for the
processing steps that are necessary prior to presentation. We
show in Figure 2B that many peptides that can bind with high
affinity to donor MHC-II variants are not presented by MHC-II
proteins. The MAPPs assay provides a unique data set that
cannot be obtained from other in vivo or ex vivo methods used
for immunogenicity assessments. We used the MAPPs as-
say to address specific hypotheses related to the processing
and presentation of FVIII-derived peptides of different product
classes.
A key issue in the immunogenicity of FVIII products is the role of
VWF, which is the chaperone of FVIII in plasma (for review, see
Pipe et al10). It has been proposed that association with VWF
protects some FVIII sites from being processed to explain
the clinical observations showing decreased immunogenicity
of pdFVIII products.5-8 Studies by Voorberg and colleagues
compared FVIII peptides identified in a MAPPs assay following
incubation of MoDCs with a BDD-rFVIII.13,26 The studies were
conducted with 2 concentrations of BDD-rFVIII, 50 nM and
25 nM, using MoDCs from 3 and 2 donors, respectively. The
studies found that VWF modulates the peptides identified in the
MAPPs assay. However, only cells from the 2 patients treated
with 25 nM showed VWF-mediated protection; that is, fewer
peptides are identified following exposure to cells of FVIII plus
VWF.
Although the hypothesis that VWF-FVIII interaction protects
FVIII processing can be tested in vitro, it is difficult to rationalize
under physiological conditions. This is because FVIII has a very
high affinity for VWF (0.2-0.5 nM)51 and infused FL-rFVIII would
associate very rapidly with endogenous VWF. In this study, we
compared FVIII-peptide presentation in the presence of pdVWF
for FL-rFVIII, BDD-rFVIII, and pdFVIII. The relative concentrations
of VWF and FVIII commercial preparations of pdFVIII vary9; we
reconstituted all proteins used in this study with the same pdVWF
at an identical molar ratio (1:13.4).
As expected, BDD-rFVIII presented fewer total and unique
peptides compared with FL-rFVIII (Figure 3) and all the peptides
not identified following incubation with BDD-rFVIII mapped to
the B domain. This finding shows that although the FL-rFVIII and
BDD-rFVIII were manufactured by different companies, the
identical peptides were recovered in a MAPPs assay (except for
the peptides in the B domain, which is lacking in the BDD-rFVIII
product).
The findings in several clinical studies that there is a higher
risk of developing inhibitors to rFVIII products than to pdFVIII
products6-9 did not provide a mechanistic explanation. Studies
have shown that a necessary condition for the immune response
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Figure 4. Comparison of FVIII peptides identified in a MAPPs assay following incubation of MoDCs with FL-rFVIII plus pdVWF or pdFVIII plus pdVWF.
(A) For each donor and HA patient, number of peptides found in the MAPPs assay for FL-rFVIII plus pdVWF (red) and pdFVIII plus pdVWF (blue) are shown. In addition, the
MHC-II–DRB1 alleles for each donor are identified as well as their respective frequencies in African, Asian, and white populations. (B) Location and frequencies of peptides for
a single donor (D1179) identified in the MAPPs assay following incubation of APCs with FL-rFVIII plus pdVWF (blue) or pdFVIII plus pdVWF (red). (C) Pooled data for all
subjects showing location and frequencies of peptides identified following incubation with FL-rFVIII plus pdVWF where no peptides were found after incubation with pdFVIII
plus pdVWF.










 user on 15 July 2020
of FVIII-derived peptides by APCs and subsequent stimulation of
FVIII-specific CD4 T lymphocytes.52,53 Thus, the MAPPs assay
could provide information about a necessary condition for
clinically relevant immune responses: MHC-II–mediated peptide
presentation. We compared the number and location of peptides
identified in the MAPPs assay when MoDCs from the same
donor/patient were incubated with either FL-rFVIII plus pdVWF
or pdFVIII plus pdVWF. All donors presented larger numbers of
peptides when incubated with FL-rFVIII plus pdVWF and
several unique peptides were identified following incubation with
FL-rFVIII plus pdVWF. Interestingly, these peptides do not necessarily
map to the regions of FVIII associated with VWF (Figure 6).
We observed (i) that pdFVIII plus pdVWF presents fewer peptides
than FL-rFVIII plus pdVWF and (ii) that the “protected” peptides do
not necessarily map onto the regions of VWF-FVIII. These observa-
tions were consistent for all subjects and suggest that the folding
and/or posttranslational modification of pdFVIII (which is synthesized
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F801 F803 D1111 D1123 D1128 D1179
Figure 5. VWF peptides identified in a MAPPs assay and effect of co-incubation with different FVIII products. (A) For each donor, number of VWF peptides
identified in the MAPPs assay is shown by the bars; pdVWF was coincubated with either FL-rFVIII (red) or pdFVIII (blue). Left panel, The MHC-II-DRB1 alleles for each donor
and their respective frequencies in African, Asian, and white populations. (B) Location of the VWF peptides identified in the MAPPs assay shown on the VWF primary





Figure 6. Mapping of the MAPPs assay derived peptides on FVIII structure. (A) Surface representation of the FVIII structure (PDB ID 2R7E) with the regions identified
to be VWF-binding sites10,39 (pink). (B) Structure depicted in panel A with the regions yielding MHC-II–presented FVIII-derived peptides unique to FL-rFVIII (green). Peptides in
green (see domain labels for peptide location) were identified on MoDCs incubated with FL-rFVIII plus pdVWF but not identified when MoDCs from the same subject were
incubated with pdFVIII plus pdVWF (ie, protected in the pdFVIII protein). The FVIII domains are identified on the figure in bold letters.
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human tissue) are less susceptible to proteolytic processing and
presentation by MoDCs. It is conceivable that the recombinant
proteins overexpressed in a heterologous system exhibit greater
microheterogeneity and less optimal folding and/or posttrans-
lational modifications. Additionally, a recent report54 shows
different glycosylation patterns in pdFVIII and FL-rFVIII, which
could also contribute to the differential enzymatic processing of
these 2 product classes. The VWF-mediated mechanisms by
which internalization of FVIII is affected11,13 would not account
for the differences observed in this study as both FL-rFVIII and
pd-FVIII were incubated with dendritic cells in the presence of
pdVWF.
Although our results are consistent with some clinical studies5-8
that show that rFVIII products may be more immunogenic than
pdFVIII products, due to the small number of HA patients in this
study it is not possible to determine whether peptides identified on
MoDCs can be used for predicting clinical immunogenicity. It is
unlikely that any technique used in isolation will be sufficient to
design predictive algorithms. Nonetheless, the MAPPs assay
generates a unique data set that provides information about both
peptide processing and presentation. It will be necessary to
integrate the MAPPs assay into clinical trials to fully understand
the mechanistic underpinnings of clinical observations. MAPPs
assays performed in conjunction with T-cell–based proliferation
assays (using peptides identified in the MAPPs assay) and
genotyping of patients (to determine which of the presented peptides
are foreign) when carried out on clinical samples would plausibly
provide key parameters for predictive algorithms for inhibitor devel-
opment both at the individual and population levels. The former would
be useful in the clinic to determine the best choice of medication
and the latter in choosing between candidate drugs during drug
development.
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Figure 7. HLAcII-DRB1 coverage in this study and comparison of FVIII peptides identified in this study and those identified in previous studies. (A) The bar
labeled “World” represents a set of 38 MHC-II–DRB1 alleles and their respective frequencies in the world population; together, these alleles represent 95.42% of alleles found in
this population. The bar labeled “Study” represents the 16 alleles found in the subjects of the MAPPS assays. This subset represents 59.89% of alleles found in the world
population. The relative frequencies of the MHC-II–DRB1 alleles in the study population and the world population are comparable. (B) Previous studies have identified FVIII peptides
in MAPPs assays using a BDD-rFVIII, whose primary amino acid sequence corresponds exactly to that of the BDD-rFVIII used in this study; the peptides identified in studies by
Peyron et al26 (green), van Haren et al25 (blue), and in the current study are shown for comparison.
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